Melatonin Loaded Nanomedicine for the Treatment of Diabetes

Neeraj Kumar, Ajay Bhatia, Nibedeeta Rani Sarraf, Indu Sharma, Tilak Raj, Rajesh Kumar, Arup Giri

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Melatonin is a hormone produced by the pineal gland that significantly regulates the sleep-wake cycle. It also acts as an antioxidant and antiinflammatory agent, making it a promising therapeutic candidate for treating several diseases, including diabetes. Nanomedicine is an emerging field involving nanoparticles to deliver therapeutic agents to specific cells or tissues. Melatonin-loaded nanomedicine is a novel approach that offers targeted delivery of melatonin to cells and tissues, thereby enhancing its therapeutic efficacy. The history of nanomedicine dates back to the early 1960s, when the concept of nanotechnology was first introduced. Since then, significant advancements have been made in nanomedicine, leading to the development of various nano-carriers for drug delivery, including liposomes, dendrimers, and polymeric nanoparticles. Melatonin-loaded nanomedicine exerts its therapeutic effects through various cellular mechanisms, including the modulation of oxidative stress, inflammation, and insulin resistance. These mechanisms play a critical role in the pathogenesis of diabetes, making melatoninbased nanomedicine a potential treatment option for this disease. In preclinical studies, melatonin-loaded nanomedicine has been shown to improve glucose homeostasis, increase insulin sensitivity, and reduce oxidative stress in animal models of diabetes. These findings suggest that melatonin-based nanomedicine has the potential to be a safe and effective therapeutic option for the treatment of diabetes. Therefore, melatoninloaded nanomedicine offers a promising therapeutic approach to treating diabetes. Its targeted delivery to specific cells and tissues and its antioxidant and anti-inflammatory properties make it a potential treatment option for this disease. Further research is needed to establish its safety and efficacy in humans, but the early results are promising. This book chapter reveals the potency and future scope of melatonin-based nanomedicine against Diabetes mellitus.

Original languageEnglish
Title of host publicationGreen Healer Anti-Diabetic Nanomedicine for the Management of Diabetes Mellitus
PublisherNova Science Publishers, Inc.
Number of pages34
ISBN (Electronic)9798886978513
StatePublished - 1 Jan 2023
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2023 by Nova Science Publishers, Inc.


Dive into the research topics of 'Melatonin Loaded Nanomedicine for the Treatment of Diabetes'. Together they form a unique fingerprint.

Cite this